Effectiveness of Zingiber officinale to reduce inflammation in community acquired pneumonia

Phase 3

Completed

• Conditions: met the diagnostic criteria of CAPconfirmed by pneumonia symptoms such as cough, change/purulence of sputum color, fever, or breathlessness had pneumonia sign by chest X-ray (infiltrate of pneumonia).; community acquired pneumonia; Zingiber officinale var rubrum; inflammatory marker; length of hospitalization

• Registration Number: TCTR20230414002
• Lead Sponsor: Indonesia Non (state budget) APBN funds of research institutions and community service

Brief Summary

In treatment group, the mean difference between post- and pre-treatment as follow IL-6 level was 9.93 pg/mL, procalcitonin level 471.31 ng/mL, and NLR value 4.01. In control group, the difference was 18.94 pg/mL for IL-6, 339.39 ng/mL for procalcitonin, and 1.56 for NLR. The change of IL-6 was not statistically significant between treatment and control groups with p 0.917. Length of stay was not statistically significant between the treatment and control groups 4.13 vs 4.47 days, p 0.361.

Detailed Description

Not available

Study Timeline

• Study Completion: 2022-09-30
• Study Start: 2023-04-14
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

1. met the diagnostic criteria of CAP
2. confirmed by pneumonia symptoms such as cough, change/purulence of sputum color, fever, or breathlessness
3. had pneumonia sign by chest X-ray (infiltrate of pneumonia).

Exclusion Criteria

1. severe CAP
2. having cardiopulmonary failure
3. physical disfunction who could not complete the study
4. patients with mental or communication disorder were excluded

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
IL-6 5 days after intervention IL-6 Human ELISA kit (DE2132) quantitative assay,PCT 5 days after intervention PCT Human ELISA kit (E-EL-H1492) quantitative assay,NLR 5 days after intervention leukocyte diffcount examination by using a blood smear and be counted manually (Neubauer)

Secondary Outcome Measures

Name	Time	Method
ength of stay 5 days after intervention Total days from admission until discharge date